https://www.selleckchem.com/pr....oducts/sp-600125.htm
Of note, we demonstrate that the ASO treatment reversed the cardiac conduction abnormalities, and this correlated with restoration of Gja5 (connexin 4 expression in the heart. This is the first time that an ASO targeting a non-CUG sequence within the DMPK 3'UTR has demonstrated benefit on the key DM1 phenotypes of myotonia and cardiac conduction defects. Our data also shows for the first time, that ASOs may be a viable option for treating cardiac pathology in DM1. © The Author(s) 2020. Published by Oxford University Press. All right
Curtir
Comentario
Compartilhar
